JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Perrigo Co PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

22.01 -3.08

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.76

Max

22.48

Pagrindiniai rodikliai

By Trading Economics

Pajamos

38M

-6.4M

Pardavimai

-94M

1B

Dividendų pajamingumas

4.22

Pelno marža

-0.613

Darbuotojai

8,379

EBITDA

13M

127M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+39.69% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.22%

2.54%

Kitas dividendų mokėjimo data

2025-09-16

Kita Ex Dividend data

2025-08-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

352M

3.7B

Ankstesnė atidarymo kaina

25.09

Ankstesnė uždarymo kaina

22.01

Naujienos nuotaikos

By Acuity

12%

88%

11 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Perrigo Co PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-14 13:01; UTC

Įsigijimai, susijungimai, perėmimai

Perrigo to Sell Dermacosmetics Business to KKR With Focus on Streamlining Company

2025-02-28 17:42; UTC

Pagrindinės rinkos jėgos

Perrigo Shares Jump on FDA's Move to Reclassify Wisconsin Infant-Formula Plant

2025-02-27 23:52; UTC

Uždarbis

Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall

2025-07-14 12:33; UTC

Įsigijimai, susijungimai, perėmimai

Perrigo: Business Generated About 5% of 2024 Adjusted Operating Income >PRGO

2025-07-14 12:33; UTC

Įsigijimai, susijungimai, perėmimai

Perrigo: Dermacosmetics Branded Business Generated About EUR125 Million Sales in 2024 >PRGO

2025-07-14 12:32; UTC

Įsigijimai, susijungimai, perėmimai

Perrigo: Deal Proceeds to Further Strengthen Balance Sheet >PRGO

2025-07-14 12:31; UTC

Įsigijimai, susijungimai, perėmimai

Perrigo: Deal Includes EUR300 Million Upfront Cash, Up to EUR27 Million Contingent Payments >PRGO

2025-07-14 12:31; UTC

Įsigijimai, susijungimai, perėmimai

Perrigo To Sell Dermacosmetics Branded Business to KKR Investment Vehicle >PRGO

2025-07-14 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Perrigo Announces Agreement to Divest Dermacosmetics Business for Up to EUR327 Million

Akcijų palyginimas

Kainos pokytis

Perrigo Co PLC Prognozė

Kainos tikslas

By TipRanks

39.69% į viršų

12 mėnesių prognozė

Vidutinis 31.5 USD  39.69%

Aukščiausias 40 USD

Žemiausias 24 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Perrigo Co PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

2

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

25.22 / 26.85Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

11 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Perrigo Co PLC

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.